Literature DB >> 15162917

Development and validation of an ELISA for hemoglobin-A2: a novel method for beta-thalassemia screening in developing countries.

Shyla R Menon1, M Ikram Khatkhatay, Sucheta P Dandekar, Zarine M Patel.   

Abstract

Hemoglobin-A2 (HbA2) measurement in human hemolysates has great significance, since its level can indicate beta-thalassemia carrier status in otherwise healthy individuals. An ELISA for HbA2 using antiserum monospecific to the delta chain of HbA2 and affinity purified antirabbit gamma globulins (ARGG) conjugated to horseradish peroxidase (HRP) have been developed. The monospecific antiserum used does not cross react with other hemoglobins. Hemolysates from volunteers are used for measurement of HbA2. In a limited trial for beta-thalassemia carrier screening (n = 350), the results obtained with the developed ELISA are comparable with those obtained with a micro-column chromatography method (r > or = 0.89). The developed ELISA is simple, accurate, precise, inexpensive, and several samples can be processed simultaneously with ease, making this system a suitable candidate for transforming into a user friendly kit.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162917     DOI: 10.1081/ias-120030523

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  3 in total

1.  Beta-thalassaemia carrier detection by ELISA: a simple screening strategy for developing countries.

Authors:  M Shyla Ravindran; Zareen M Patel; M Ikram Khatkhatay; S P Dandekar
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  Sandwich ELISA for hemoglobin A2 quantification and identification of beta-thalassemia carriers.

Authors:  Surakit Kuntaruk; Thanusak Tatu; Tiemjan Keowkarnkah; Watchara Kasinrerk
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

Review 3.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.